The cohort included 74 patients with a primary lesion in the left-sided colon, while 15 patients had a primary lesion in the right-sided colon. The response rate (RR) was 3.4%. The disease control rate (DCR) was 52.8%. The median PFS (mPFS) and OS (mOS) were 3.5 months (95% ...
Nurses play an important role in the administration of biosimilars and the education of patients receiving them. The first role for oncology nurses is to understand the function of biosimilars compared with that of biologics. It is also important that they review the prescribing information...
Interestingly, a positive association has been described with the development of immune-related adverse events after the use of ICI therapy and progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). However, for higher toxicities, this association was observed ...
Background In international prognostic index (IPI) risk-tailored adult patients with diffuse large B-cell lymphoma (DLBCL), it is still unclear whether the... BT Huang,QC Zeng,J Yu,... - 《Journal of Cancer Research & Clinical Oncology》 被引量: 55发表: 2012年 Circulating microRNA-125b...
in the prevention of autoimmune reactions [1]. However, the same mechanisms can be exploited by cancer cells to elude immune system attack [2]. Indeed, it is well known that the upregulation of these molecules in immune cells infiltrating the tumor microenvironment (TME) or on cancer cells ...
A recent meta-analysis concluded that maintenance chemotherapy was associated with increased toxicity but no significant improvement in progression-free survival (PFS) or overall survival (OS) [10]. There is ongoing interest in investigating other agents, such as targeted therapies in the maintenance ...
Divarasib is a G12C inhibitor similar to sotorasib and adagrasib; however, it is 5–20 times more potent and up to 50 times more selective [14]. In a phase 1 trial of 137 patients, including 60 NSCLC patients [15], the ORR and median PFS were 53 % and 13 months in patients ...
[76,77]. However, its clinical value was not further validated in subsequently pivotal phase III trial (ECHO-301/KEYNOTE-252)[78] when the number of enrolled patients increased – the addition of epacadostat to pembrolizumab failed to improve progression-free survival (PFS) in patients with ...
There have been many recent clinical trials assessing the efficacy of PARPis in patients with recurrent or primary ovarian cancer [10,11,12,13,14,15,16,17,18]. This showed that PARPis significantly prolong the PFS as a maintenance treatment after response (CR/PR) to platinum-based ...
EP: 15.What is on the Horizon for Adjuvant Therapy in Early-Stage Breast Cancer?Transcript: Rachel Layman, MD: This has been a great conversation. I was curious, what up-and-coming things are you looking forward to in the adjuvant setting?Stephanie...